Tiziana touts multiple sclerosis win at lower dose as high dose misses mark - BioSpace
BioSpace · Nov 2, 3:23 PM
Tiziana Life Sciences reports positive phase 2a results for Intranasal Foralumab in MS - Yahoo Finance
Yahoo Finance · Nov 2, 2:48 PM
Lower dose of Tiziana's MS drug reduces neuroinflammation, while higher dose struggles - Fierce Biotech
Fierce Biotech · Nov 2, 1:37 PM
Market reactionShares fell 16% on Nov 2.
Tiziana Life Sciences is a clinical-stage company developing foralumab, a nasal-spray antibody for multiple sclerosis, Alzheimer's disease and multiple system atrophy; it is not approved.
Tiziana's case rests on intranasal foralumab reducing brain inflammation. INFORM-MS in non-active secondary progressive MS has completed its last patient visit; PET-led topline results are now expected in Q4 2026. Early/mild Alzheimer's enrollment and dosing initiation are complete, with topline data anticipated in Q1 2027. Financing remains critical: cash was $3.9M at 16 October 2026, and the approximately $8.6 million January 2026 raise did not eliminate the need for additional capital.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: INFORM-MS shows less brain inflammation than placebo
Does intranasal foralumab reduce PET-measured brain inflammation versus placebo, with supportive disability and fatigue outcomes?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Foralumab awaits INFORM-MS results as financing needs persist
Foralumab's multi-indication neuroinflammation bet hinges on whether na-SPMS Phase 2a and AD interim data demonstrate reproducible efficacy beyond open-label signals
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Neurology and pain, Infectious diseases, Lung and respiratory diseases, Obesity, diabetes and heart disease, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
28 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.